Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma
Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods....
Gespeichert in:
Veröffentlicht in: | Gynecologic oncology 2007-06, Vol.105 (3), p.625-629 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 629 |
---|---|
container_issue | 3 |
container_start_page | 625 |
container_title | Gynecologic oncology |
container_volume | 105 |
creator | Shvartsman, Hyun S Sun, Charlotte C Bodurka, Diane C Mahajan, Vrinda Crispens, Marta Lu, Karen H Deavers, Michael T Malpica, Anais Silva, Elvio G Gershenson, David M |
description | Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types. |
doi_str_mv | 10.1016/j.ygyno.2007.01.030 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70531906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0090825807000558</els_id><sourcerecordid>70531906</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</originalsourceid><addsrcrecordid>eNqFUsuu0zAQjRCIWy58ARLyil3C2HkvQEIVj0pXYsFjazn2pHVJ7GI7rbLjH_g1voAvwbntFRILWFn2ecx4ziTJUwoZBVq92GfzdjY2YwB1BjSDHO4lKwptmVZN2d5PVgAtpA0rm6vkkfd7gEih7GFyReucAS2rVfJzbceDcNpbQ2xPwg6JHLTRUgykw504ausWwOBpmInSYmusR0V8EFv0ZLP59f3H5gsZ7CndOqGQeHR28kQKJ7Wxo7hztUfhZnLSYRevIizPF-qCaGFImEbr_AJENzKKQW-NMIEcbEATdGzoVuhQTo4I_4-aj5MHvRg8Prmc18nnt28-rd-nNx_ebdavb1JZUBZSVTR9QXNVq7YVTS8qSivGRNvkiKprC9GXrBey6AqJrK971Uvoqk622DCa501-nTw_-x6c_TahD3zUXuIwCIOxIV5DmdMWqkjMz0TprPcOe35weowD4RT4Eibf89sw-RImB8pjUlH17GI_dSOqP5pLepHw8kzA-MmjRse91GgkKh2nFLiy-j8FXv2lv8v-K87o93ZyJs6PU-4ZB_5x2adlnaCOq1SWTf4bDQDNrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70531906</pqid></control><display><type>article</type><title>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Shvartsman, Hyun S ; Sun, Charlotte C ; Bodurka, Diane C ; Mahajan, Vrinda ; Crispens, Marta ; Lu, Karen H ; Deavers, Michael T ; Malpica, Anais ; Silva, Elvio G ; Gershenson, David M</creator><creatorcontrib>Shvartsman, Hyun S ; Sun, Charlotte C ; Bodurka, Diane C ; Mahajan, Vrinda ; Crispens, Marta ; Lu, Karen H ; Deavers, Michael T ; Malpica, Anais ; Silva, Elvio G ; Gershenson, David M</creatorcontrib><description>Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2007.01.030</identifier><identifier>PMID: 17320156</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Cystadenocarcinoma, Serous - drug therapy ; Cystadenocarcinoma, Serous - pathology ; Cystadenocarcinoma, Serous - radiotherapy ; Cystadenocarcinoma, Serous - surgery ; Disease-Free Survival ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Low-grade serous carcinoma ; Middle Aged ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Obstetrics and Gynecology ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - radiotherapy ; Ovarian Neoplasms - surgery ; Serous ovarian tumor of low malignant potential ; Survival Rate</subject><ispartof>Gynecologic oncology, 2007-06, Vol.105 (3), p.625-629</ispartof><rights>2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</citedby><cites>FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ygyno.2007.01.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17320156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shvartsman, Hyun S</creatorcontrib><creatorcontrib>Sun, Charlotte C</creatorcontrib><creatorcontrib>Bodurka, Diane C</creatorcontrib><creatorcontrib>Mahajan, Vrinda</creatorcontrib><creatorcontrib>Crispens, Marta</creatorcontrib><creatorcontrib>Lu, Karen H</creatorcontrib><creatorcontrib>Deavers, Michael T</creatorcontrib><creatorcontrib>Malpica, Anais</creatorcontrib><creatorcontrib>Silva, Elvio G</creatorcontrib><creatorcontrib>Gershenson, David M</creatorcontrib><title>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Cystadenocarcinoma, Serous - drug therapy</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Cystadenocarcinoma, Serous - radiotherapy</subject><subject>Cystadenocarcinoma, Serous - surgery</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Low-grade serous carcinoma</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Obstetrics and Gynecology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - radiotherapy</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Serous ovarian tumor of low malignant potential</subject><subject>Survival Rate</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUsuu0zAQjRCIWy58ARLyil3C2HkvQEIVj0pXYsFjazn2pHVJ7GI7rbLjH_g1voAvwbntFRILWFn2ecx4ziTJUwoZBVq92GfzdjY2YwB1BjSDHO4lKwptmVZN2d5PVgAtpA0rm6vkkfd7gEih7GFyReucAS2rVfJzbceDcNpbQ2xPwg6JHLTRUgykw504ausWwOBpmInSYmusR0V8EFv0ZLP59f3H5gsZ7CndOqGQeHR28kQKJ7Wxo7hztUfhZnLSYRevIizPF-qCaGFImEbr_AJENzKKQW-NMIEcbEATdGzoVuhQTo4I_4-aj5MHvRg8Prmc18nnt28-rd-nNx_ebdavb1JZUBZSVTR9QXNVq7YVTS8qSivGRNvkiKprC9GXrBey6AqJrK971Uvoqk622DCa501-nTw_-x6c_TahD3zUXuIwCIOxIV5DmdMWqkjMz0TprPcOe35weowD4RT4Eibf89sw-RImB8pjUlH17GI_dSOqP5pLepHw8kzA-MmjRse91GgkKh2nFLiy-j8FXv2lv8v-K87o93ZyJs6PU-4ZB_5x2adlnaCOq1SWTf4bDQDNrA</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Shvartsman, Hyun S</creator><creator>Sun, Charlotte C</creator><creator>Bodurka, Diane C</creator><creator>Mahajan, Vrinda</creator><creator>Crispens, Marta</creator><creator>Lu, Karen H</creator><creator>Deavers, Michael T</creator><creator>Malpica, Anais</creator><creator>Silva, Elvio G</creator><creator>Gershenson, David M</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</title><author>Shvartsman, Hyun S ; Sun, Charlotte C ; Bodurka, Diane C ; Mahajan, Vrinda ; Crispens, Marta ; Lu, Karen H ; Deavers, Michael T ; Malpica, Anais ; Silva, Elvio G ; Gershenson, David M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-d48f413d7d99a8fa611622a983eedb94af52fac4b4ce2f7fdfc0b6bc9e8213383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Cystadenocarcinoma, Serous - drug therapy</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Cystadenocarcinoma, Serous - radiotherapy</topic><topic>Cystadenocarcinoma, Serous - surgery</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Low-grade serous carcinoma</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Obstetrics and Gynecology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - radiotherapy</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Serous ovarian tumor of low malignant potential</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shvartsman, Hyun S</creatorcontrib><creatorcontrib>Sun, Charlotte C</creatorcontrib><creatorcontrib>Bodurka, Diane C</creatorcontrib><creatorcontrib>Mahajan, Vrinda</creatorcontrib><creatorcontrib>Crispens, Marta</creatorcontrib><creatorcontrib>Lu, Karen H</creatorcontrib><creatorcontrib>Deavers, Michael T</creatorcontrib><creatorcontrib>Malpica, Anais</creatorcontrib><creatorcontrib>Silva, Elvio G</creatorcontrib><creatorcontrib>Gershenson, David M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shvartsman, Hyun S</au><au>Sun, Charlotte C</au><au>Bodurka, Diane C</au><au>Mahajan, Vrinda</au><au>Crispens, Marta</au><au>Lu, Karen H</au><au>Deavers, Michael T</au><au>Malpica, Anais</au><au>Silva, Elvio G</au><au>Gershenson, David M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>105</volume><issue>3</issue><spage>625</spage><epage>629</epage><pages>625-629</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>Abstract Background. Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types. Methods. All patients with stages II–IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves. Results. We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P = 0.37), progression-free survival time (19.5 vs. 25 months; P = 0.92), or overall survival time (81.8 vs. 82.8 months; P = 0.84). Conclusions. The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II–IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>17320156</pmid><doi>10.1016/j.ygyno.2007.01.030</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-8258 |
ispartof | Gynecologic oncology, 2007-06, Vol.105 (3), p.625-629 |
issn | 0090-8258 1095-6859 |
language | eng |
recordid | cdi_proquest_miscellaneous_70531906 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Adolescent Adult Aged Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - pathology Cystadenocarcinoma, Serous - radiotherapy Cystadenocarcinoma, Serous - surgery Disease-Free Survival Female Hematology, Oncology and Palliative Medicine Humans Low-grade serous carcinoma Middle Aged Neoplasm Recurrence, Local - pathology Neoplasm Staging Obstetrics and Gynecology Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovarian Neoplasms - radiotherapy Ovarian Neoplasms - surgery Serous ovarian tumor of low malignant potential Survival Rate |
title | Comparison of the clinical behavior of newly diagnosed stages II–IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T20%3A02%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20clinical%20behavior%20of%20newly%20diagnosed%20stages%20II%E2%80%93IV%20low-grade%20serous%20carcinoma%20of%20the%20ovary%20with%20that%20of%20serous%20ovarian%20tumors%20of%20low%20malignant%20potential%20that%20recur%20as%20low-grade%20serous%20carcinoma&rft.jtitle=Gynecologic%20oncology&rft.au=Shvartsman,%20Hyun%20S&rft.date=2007-06-01&rft.volume=105&rft.issue=3&rft.spage=625&rft.epage=629&rft.pages=625-629&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2007.01.030&rft_dat=%3Cproquest_cross%3E70531906%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70531906&rft_id=info:pmid/17320156&rft_els_id=1_s2_0_S0090825807000558&rfr_iscdi=true |